These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29276288)

  • 21. Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.
    Sessink PJ; Trahan J; Coyne JW
    Hosp Pharm; 2013 Mar; 48(3):204-12. PubMed ID: 24421463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners.
    Khaira M; Guy AL
    J Oncol Pharm Pract; 2022 Jun; 28(4):805-815. PubMed ID: 34000919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developing a flowchart to evaluate the use of Closed System Drug-Transfer Devices with monoclonal antibodies: Focus on the clinical trial setting.
    Simal I; Bauters T; Paepens C; Clottens N; Ramaut P; Kestens E
    J Oncol Pharm Pract; 2023 Dec; 29(8):2014-2022. PubMed ID: 37680124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Environmental contamination, product contamination and workers exposure using a robotic system for antineoplastic drug preparation.
    Sessink PJ; Leclercq GM; Wouters DM; Halbardier L; Hammad C; Kassoul N
    J Oncol Pharm Pract; 2015 Apr; 21(2):118-27. PubMed ID: 24567041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beating the Spread: Developing a Simulation Analog for Contagious Body Fluids.
    Drew JL; Turner J; Mugele J; Hasty G; Duncan T; Zaiser R; Cooper D
    Simul Healthc; 2016 Apr; 11(2):100-5. PubMed ID: 27043095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the efficacy of additional measures introduced for the protection of healthcare personnel handling antineoplastic drugs.
    Odraska P; Dolezalova L; Kuta J; Oravec M; Piler P; Blaha L
    Ann Occup Hyg; 2013 Mar; 57(2):240-50. PubMed ID: 22926784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testing an Intervention to Decrease Healthcare Workers' Exposure to Antineoplastic Agents.
    Graeve C; McGovern PM; Arnold S; Polovich M
    Oncol Nurs Forum; 2017 Jan; 44(1):E10-E19. PubMed ID: 27991608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating Six Commercially Available Closed-System Drug-Transfer Devices Against NIOSH's 2015 Draft Vapor Protocol.
    Halloush S; Reveles IA; Koeller J
    Hosp Pharm; 2020 Dec; 55(6):391-399. PubMed ID: 33245720
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents.
    Clark BA; Sessink PJ
    J Oncol Pharm Pract; 2013 Jun; 19(2):99-104. PubMed ID: 23292973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Industry Perspective on the Challenges of Using Closed System Transfer Devices with Biologics and Communication Guidance to Healthcare Professionals.
    Gopalrathnam G; Christian TR; Jagannathan B; Petoskey F; Kühnle B; Weiser S; Kagdi R; Saluja S; Bhattacharyya A; Burton L; Zamiri C; Hanley K
    J Pharm Sci; 2021 Jun; 110(6):2329-2335. PubMed ID: 33617871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence of exposure to cytostatic drugs in healthcare staff: a review of recent literature.
    Martín Lancharro P; De Castro-Acuña Iglesias N; González-Barcala FJ; Moure González JD
    Farm Hosp; 2016 Nov; 40(n06):604-621. PubMed ID: 27894231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies.
    Connor TH; Sessink PJ; Harrison BR; Pretty JR; Peters BG; Alfaro RM; Bilos A; Beckmann G; Bing MR; Anderson LM; Dechristoforo R
    Am J Health Syst Pharm; 2005 Mar; 62(5):475-84. PubMed ID: 15745910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).
    Sumikawa S; Yakushijin Y; Aogi K; Yano T; Hiroki ; Hashimoto ; Tsukui C; Noguchi T; Shiraishi T; Horikawa Y; Yasuoka Y; Tanaka A; Hidaka N; Tanaka M
    Sci Rep; 2022 Jan; 12(1):139. PubMed ID: 34996936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy Safe Handling: Limiting Nursing Exposure With a Hazardous Drug Control Program.
    Crickman R
    Clin J Oncol Nurs; 2017 Feb; 21(1):73-78. PubMed ID: 28107320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to Precautionary Guidelines for Compounding Antineoplastic Drugs: A Survey of Nurses and Pharmacy Practitioners.
    Boiano JM; Steege AL; Sweeney MH
    J Occup Environ Hyg; 2015; 12(9):588-602. PubMed ID: 25897702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Container closure integrity testing and process validation of closed system transfer devices for aseptic reconstitution of drug vials connected to fluid bags.
    van den Berg RB; Akgöl K; Swart EL; Nuijen B; Crul M
    Eur J Hosp Pharm; 2024 Jun; 31(4):358-362. PubMed ID: 36792349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of personal protective equipment among health care personnel: Results of clinical observations and simulations.
    Kang J; O'Donnell JM; Colaianne B; Bircher N; Ren D; Smith KJ
    Am J Infect Control; 2017 Jan; 45(1):17-23. PubMed ID: 28065328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evaluation of two closed-system drug transfer device in the antineoplastic drug elaboration process].
    Gómez-Álvarez S; Porta-Oltra B; Hernandez-Griso M; Pérez-Labaña F; Climente-Martí M
    Farm Hosp; 2016 Jan; 40(1):36-43. PubMed ID: 26882832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ebola virus disease: The use of fluorescents as markers of contamination for personal protective equipment.
    Bell T; Smoot J; Patterson J; Smalligan R; Jordan R
    IDCases; 2015; 2(1):27-30. PubMed ID: 26793445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.